Abstract 34P
Background
Social support is an important determinant of optimal care and maybe extended by community partners including non-governmental organizations to enhance the well-being of individuals living with cancer. We determined whether social support mediated the association between unmet needs and happiness in women with early breast cancer in a multiethnic Asian setting.
Methods
The study employed a hospital-based cross-sectional design that recruited 400 multiethnic patients newly diagnosed with early breast cancer in seven tertiary Malaysian hospitals. Study tools included Multi-dimensional Scale of Perceived Social Support, Needs Assessment Tool for Breast Cancer and Oxford, Happiness Questionnaire. Partial least square structural equation modelling was used to determine the mediating role of social support in the association between unmet needs and happiness.
Results
Participants comprised Malays (58.3%), followed by Chinese (26.8%), and Indians (12.3%). Two-thirds were recruited from Ministry of Health-owned hospitals, 20.5% from academic and 14.8% from private hospitals. A majority were diagnosed with stage II (32.3%) or stage III (30.0%) breast cancer at initial diagnosis. About 5.3% of participants reported to be unhappy, 5.8% somewhat unhappy, 8.3% rather unhappy, 30.3% somewhat happy, 28.7% rather happy, and 21.8% happy. A majority had moderate-level unmet supportive care needs (74%), with the highest level of unmet needs in the domains of information services (31.3%) and hospital appointments (30.3%). Sixty per cent reported a high level of social support. Unmet needs were found to have a negative and significant effect on happiness (f 2 =8.0%, β = −0.259, p < 0.001). Social support significantly, positively, and partially mediated the association between unmet needs and, with the p-values significant for both direct (p < 0.001) and indirect (p = 0.024) effects.
Conclusions
Social support plays an important role in bridging unmet needs and improving well-being of women with breast cancer. Study findings are expected to foster greater public-private partnerships in engaging communities to actively play a role in improving life after (breast) cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Ministry of Higher Education, Malaysia.
Disclosure
R. Kaur: Financial Interests, Personal, Speaker, Consultant, Advisor: Novartis, AstraZeneca, Pfizer, Roche,. M. Thiagarajan: Non-Financial Interests, Institutional, Leadership Role: Malaysian Oncological Society, President. N.F. Bt Abdul Satar: Financial Interests, Personal, Advisory Board: Novartis, Zuellig Pharma,Ipsen Pharma, Eisai, MSD Malaysia,Pfizer, Roche,; Financial Interests, Personal, Funding: KURA Oncology, Viracta Therapeutics, MSD Malaysia, Naluri Sdn Bhd; Financial Interests, Institutional, Principal Investigator: KURA Oncology, Viracta Therapeutics, MSD Malaysia, Naluri Sdn Bhd; Non-Financial Interests, Personal, Leadership Role: Project Lead for Cancer ECHO UM. A. Ali: Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca. F.L.T. Chong: Financial Interests, Personal, Invited Speaker: Novartis, Roche,; Financial Interests, Personal and Institutional, Principal Investigator: Novartis, J&J. A.F. Abdul Aziz: Financial Interests, Personal, Invited Speaker: Roche; Non-Financial Interests, Institutional, Member of Board of Directors: National Cancer Society Malaysia; Non-Financial Interests, Institutional, Member: Fellow of College of Surgeons, Academy of Medicine Malaysia Member of Malaysian Oncological Society. C.H. Yip: Financial Interests, Personal, Advisory Board: AstraZeneca. N. Bhoo-Pathy: Financial Interests, Personal, Funding: Partial funding from Ministry of Higher Education. All other authors have declared no conflicts of interest.
Resources from the same session
551P - Real-world incidence and outcomes of immune-related adverse events in NSCLC patients
Presenter: Andrea Knox
Session: Poster Display
Resources:
Abstract
552P - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Presenter: Yasushi Goto
Session: Poster Display
Resources:
Abstract
553P - Preceding plasma EGFR vs upfront tissue NGS for advanced NSCLC in the Chinese population: A single centre experience in Hong Kong
Presenter: Janet Du
Session: Poster Display
Resources:
Abstract
554P - Comparison of the analytical performance of endobronchial ultrasound-guided transbronchial needle aspiration and other sampling methods for the Oncomine Dx target test: An observational study
Presenter: Kazuhito Miyazaki
Session: Poster Display
Resources:
Abstract
555P - Quality of life in patients with stage IV non-small cell lung cancer and the influence of druggable mutations over time: A prospective, territory-wide study in Hong Kong
Presenter: Jason C S Ho
Session: Poster Display
Resources:
Abstract
556P - Results from the phase I study on efficacy and safety of iruplinalkib (WX-0593) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who received prior second-generation ALK tyrosine kinase inhibitors (TKIs)
Presenter: xuezhi Hao
Session: Poster Display
Resources:
Abstract
557P - Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy
Presenter: Shasha Wang
Session: Poster Display
Resources:
Abstract
558P - Treatment duration and adherence of brigatinib as second-line treatment after crizotinib for ALK+ NSCLC in South Korea
Presenter: Jeong Eun Lee
Session: Poster Display
Resources:
Abstract
559P - Comprehensive survey of AACR GENIE database revealed a wide range of TMB distribution among all three classes (I, II, III) of BRAF mutated NSCLC
Presenter: Zhaohui Arter
Session: Poster Display
Resources:
Abstract
560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Presenter: Chengdi Weng
Session: Poster Display
Resources:
Abstract